Icenticaftor, Novel Therapy for COPD: This Glass Is Half Full.
作者信息
Rennard Stephen I
机构信息
Department of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska.
出版信息
Am J Respir Crit Care Med. 2023 Aug 15;208(4):346-348. doi: 10.1164/rccm.202307-1175ED.
Abstract
摘要
相似文献
1
Icenticaftor, Novel Therapy for COPD: This Glass Is Half Full.依西托佛，慢性阻塞性肺疾病的新型疗法：这杯水还有半杯呢。
Am J Respir Crit Care Med. 2023 Aug 15;208(4):346-348. doi: 10.1164/rccm.202307-1175ED.
2
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.Icenticaftor（QBW251）的发现，一种囊性纤维化跨膜电导调节剂增强剂，在囊性纤维化和慢性阻塞性肺疾病中具有临床疗效。
J Med Chem. 2021 Jun 10;64(11):7241-7260. doi: 10.1021/acs.jmedchem.1c00343. Epub 2021 May 24.
3
Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).囊性纤维化跨膜电导调节因子增效剂 icenticaftor（QBW251）的安全性和疗效。
J Cyst Fibros. 2021 Mar;20(2):250-256. doi: 10.1016/j.jcf.2020.11.002. Epub 2020 Dec 6.
4
Cigarette Smoke-Induced Acquired Dysfunction of Cystic Fibrosis Transmembrane Conductance Regulator in the Pathogenesis of Chronic Obstructive Pulmonary Disease.香烟烟雾引起的囊性纤维化跨膜电导调节因子获得性功能障碍在慢性阻塞性肺疾病发病机制中的作用。
Oxid Med Cell Longev. 2018 Apr 23;2018:6567578. doi: 10.1155/2018/6567578. eCollection 2018.
5
CFTR dysfunction and targeted therapies: A vision from non-cystic fibrosis bronchiectasis and COPD.囊性纤维化跨膜传导调节因子功能障碍与靶向治疗：来自非囊性纤维化支气管扩张症和慢性阻塞性肺疾病的视角
J Cyst Fibros. 2022 Sep;21(5):741-744. doi: 10.1016/j.jcf.2022.04.018. Epub 2022 May 9.
6
CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease.囊性纤维化和慢性阻塞性肺疾病中的 CFTR 功能障碍。
Expert Rev Respir Med. 2018 Jun;12(6):483-492. doi: 10.1080/17476348.2018.1475235. Epub 2018 May 23.
7
Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance.慢性支气管炎及其他黏液清除疾病中获得性囊性纤维化跨膜传导调节因子功能障碍
Clin Chest Med. 2016 Mar;37(1):147-58. doi: 10.1016/j.ccm.2015.11.003. Epub 2015 Dec 24.
8
Cystic Fibrosis Transmembrane Conductance Regulator. Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.囊性纤维化跨膜传导调节因子。在囊性纤维化和慢性阻塞性肺疾病中的意义。
Ann Am Thorac Soc. 2016 Apr;13 Suppl 2:S150-5. doi: 10.1513/AnnalsATS.201509-588KV.
9
Pilot evaluation of ivacaftor for chronic bronchitis.依伐卡托治疗慢性支气管炎的初步评估。
Lancet Respir Med. 2016 Jun;4(6):e32-3. doi: 10.1016/S2213-2600(16)30047-9. Epub 2016 May 16.
10
Cystic Fibrosis Transmembrane Conductance Regulator: Roles in Chronic Obstructive Pulmonary Disease.囊性纤维化跨膜电导调节因子：在慢性阻塞性肺疾病中的作用。
Am J Respir Crit Care Med. 2022 Mar 15;205(6):631-640. doi: 10.1164/rccm.202109-2064TR.
引用本文的文献
1
Reply to Gan .回复甘。
Am J Respir Crit Care Med. 2023 Nov 15;208(10):1141-1142. doi: 10.1164/rccm.202309-1653LE.
本文引用的文献
1
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.依伐卡托，一种 CFTR 增效剂，在 COPD 中的应用：一项多中心、平行分组、双盲临床试验。
Am J Respir Crit Care Med. 2023 Aug 15;208(4):417-427. doi: 10.1164/rccm.202303-0458OC.
2
Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging.使用多重免疫荧光和多光谱成像进行空间生物学研究的伴随诊断要求。
Front Mol Biosci. 2023 Feb 9;10:1051491. doi: 10.3389/fmolb.2023.1051491. eCollection 2023.
3
Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment.基于液体活检的伴随诊断在非小细胞肺癌治疗中的临床应用
Explor Target Antitumor Ther. 2022;3(5):630-642. doi: 10.37349/etat.2022.00104. Epub 2022 Oct 31.
4
Molecular Biomarkers of Response to Cancer Immunotherapy.癌症免疫治疗反应的分子生物标志物。
Clin Lab Med. 2022 Sep;42(3):469-484. doi: 10.1016/j.cll.2022.05.004. Epub 2022 Aug 22.
5
Cystic Fibrosis Transmembrane Conductance Regulator: Roles in Chronic Obstructive Pulmonary Disease.囊性纤维化跨膜电导调节因子：在慢性阻塞性肺疾病中的作用。
Am J Respir Crit Care Med. 2022 Mar 15;205(6):631-640. doi: 10.1164/rccm.202109-2064TR.
6
Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine.慢性阻塞性肺疾病中囊性纤维化跨膜调节因子功能障碍作为个性化医疗的潜在靶点
Biomedicines. 2021 Oct 10;9(10):1437. doi: 10.3390/biomedicines9101437.
7
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.Icenticaftor（QBW251）的发现，一种囊性纤维化跨膜电导调节剂增强剂，在囊性纤维化和慢性阻塞性肺疾病中具有临床疗效。
J Med Chem. 2021 Jun 10;64(11):7241-7260. doi: 10.1021/acs.jmedchem.1c00343. Epub 2021 May 24.
8
Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial.ICENTICAFTOR（QBW251）在 COPD 中的疗效和安全性：一项 2 期随机试验的结果。
Int J Chron Obstruct Pulmon Dis. 2020 Oct 5;15:2399-2409. doi: 10.2147/COPD.S257474. eCollection 2020.
9
Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.囊性纤维化：高效靶向治疗药物的出现及其潜在的临床意义。
Am J Respir Crit Care Med. 2020 May 15;201(10):1193-1208. doi: 10.1164/rccm.201910-1943SO.
10
Precision medicine in COPD: where are we and where do we need to go?慢性阻塞性肺疾病精准医学：我们身在何处，又需要去往何方？
Eur Respir Rev. 2018 Aug 1;27(149). doi: 10.1183/16000617.0022-2018. Print 2018 Sep 30.
Zotero 插件